image
Healthcare - Medical - Healthcare Information Services - NASDAQ - US
$ 23.72
-9.31 %
$ 1.74 B
Market Cap
-9.17
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on May, 7, 2025.

The intrinsic value of one SDGR stock under the worst case scenario is HIDDEN Compared to the current market price of 23.7 USD, Schrödinger, Inc. is HIDDEN

This DCF valuation model was last updated on May, 7, 2025.

The intrinsic value of one SDGR stock under the base case scenario is HIDDEN Compared to the current market price of 23.7 USD, Schrödinger, Inc. is HIDDEN

This DCF valuation model was last updated on May, 7, 2025.

The intrinsic value of one SDGR stock under the best case scenario is HIDDEN Compared to the current market price of 23.7 USD, Schrödinger, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart SDGR

image
$27.0$27.0$26.0$26.0$25.0$25.0$24.0$24.0$23.0$23.0$22.0$22.0$21.0$21.0$20.0$20.0$19.0$19.0$18.0$18.0$17.0$17.015 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '25
FINANCIALS
208 M REVENUE
-4.21%
-209 M OPERATING INCOME
-17.95%
-187 M NET INCOME
-459.54%
-157 M OPERATING CASH FLOW
-15.09%
149 M INVESTING CASH FLOW
-22.90%
10.1 M FINANCING CASH FLOW
11.88%
88.3 M REVENUE
150.26%
-20.7 M OPERATING INCOME
69.73%
-40.2 M NET INCOME
-5.45%
-31.1 M OPERATING CASH FLOW
6.44%
23.5 M INVESTING CASH FLOW
-74.12%
119 K FINANCING CASH FLOW
-69.64%
Balance Sheet Schrödinger, Inc.
image
Current Assets 635 M
Cash & Short-Term Investments 352 M
Receivables 255 M
Other Current Assets 27.5 M
Non-Current Assets 188 M
Long-Term Investments 43.2 M
PP&E 136 M
Other Non-Current Assets 8.95 M
42.77 %31.02 %3.34 %5.25 %16.53 %Total Assets$823.2m
Current Liabilities 192 M
Accounts Payable 10.7 M
Short-Term Debt 0
Other Current Liabilities 181 M
Non-Current Liabilities 210 M
Long-Term Debt 0
Other Non-Current Liabilities 210 M
45.07 %52.28 %Total Liabilities$401.8m
EFFICIENCY
Earnings Waterfall Schrödinger, Inc.
image
Revenue 208 M
Cost Of Revenue 75.5 M
Gross Profit 132 M
Operating Expenses 341 M
Operating Income -209 M
Other Expenses -22.2 M
Net Income -187 M
250m250m200m200m150m150m100m100m50m50m00(50m)(50m)(100m)(100m)(150m)(150m)(200m)(200m)(250m)(250m)208m(75m)132m(341m)(209m)22m(187m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
63.64% GROSS MARGIN
63.64%
-100.85% OPERATING MARGIN
-100.85%
-90.16% NET MARGIN
-90.16%
-44.40% ROE
-44.40%
-22.73% ROA
-22.73%
-33.40% ROIC
-33.40%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Schrödinger, Inc.
image
20m20m00(20m)(20m)(40m)(40m)(60m)(60m)(80m)(80m)(100m)(100m)(120m)(120m)(140m)(140m)(160m)(160m)(180m)(180m)2018201820192019202020202021202120222022202320232024202420252025
Net Income -187 M
Depreciation & Amortization 6.16 M
Capital Expenditures -7.31 M
Stock-Based Compensation 49.9 M
Change in Working Capital -13 M
Others 150 M
Free Cash Flow -165 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Schrödinger, Inc.
image
Wall Street analysts predict an average 1-year price target for SDGR of $28.5 , with forecasts ranging from a low of $27 to a high of $30 .
SDGR Lowest Price Target Wall Street Target
27 USD 13.83%
SDGR Average Price Target Wall Street Target
28.5 USD 20.15%
SDGR Highest Price Target Wall Street Target
30 USD 26.48%
Price
Max Price Target
Min Price Target
Average Price Target
30302828262624242222202018181616Jun '24Jun '24Jul '24Jul '24Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 9
6. Ownership
Insider Ownership Schrödinger, Inc.
image
Sold
0-3 MONTHS
662 K USD 4
3-6 MONTHS
97.1 K USD 4
6-9 MONTHS
27.2 K USD 1
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Schrödinger Reports Strong First Quarter 2025 Financial Results NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. today announced financial results for the quarter ended March 31, 2025. businesswire.com - 1 week ago
Schrödinger to Present at BofA Securities 2025 Healthcare Conference NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today announced that management will participate in a fireside chat at the BofA Securities 2025 Healthcare Conference. The live presentation will take place on Wednesday, May 14, 2025 at 4:40 p.m. ET. The live webcast can be accessed in the “Investors” section of Schrödinger's website and will be archived for approximately 90 days following the event. About Schrödinger Schrödinger is transforming molecular discovery with its computatio. businesswire.com - 2 weeks ago
Schrödinger Presents New Preclinical Data at AACR Annual Meeting CHICAGO--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) presented preclinical data on SGR-3515, its investigational Wee1/Myt1 co-inhibitor today at the American Association for Cancer Research (AACR) Annual Meeting 2025. The data demonstrated that SGR-3515 has improved anti-tumor activity in preclinical models compared to known Wee1 and Myt1 monotherapy inhibitors. The poster also described how the dosing schedule of SGR-3515 can be optimized to preserve efficacy and minimize target-related. businesswire.com - 3 weeks ago
Schrödinger to Announce First Quarter 2025 Financial Results on May 7 NEW YORK--(BUSINESS WIRE)--Schrödinger will report its first quarter 2025 financial results on Wednesday, May 7, 2025, after the financial markets close. businesswire.com - 3 weeks ago
3 Momentum Stocks That Could Soar Post-Market Volatility While the impact of unanticipated tariff policy changes in early April was market-wide, the recovery has been less even. Despite a major rebound following the sell-off, some firms have been sluggish to reclaim lost ground. marketbeat.com - 4 weeks ago
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today reported that on April 16, 2025, the company granted (i) a non-statutory stock option to purchase 3,300 shares of the company's common stock to one newly hired employee and (ii) restricted stock units (RSUs) with respect to 12,866 shares of the company's common stock to six newly hired employees. These grants were made pursuant to the company's 2021 Inducement Equity Incentive Plan, were approved by the compensation committee of. businesswire.com - 1 month ago
Schrödinger's Statement Regarding FDA Plan to Phase Out Animal Testing Requirement for Monoclonal Antibodies and Other Drugs NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) strongly supports the U.S. Food and Drug Administration's (FDA) plan to reduce, refine or potentially replace current animal testing requirements with new approaches designed to improve drug safety and accelerate the evaluation process, while reducing animal experimentation. The FDA's roadmap encourages a number of computational approaches to predict drug properties. Schrödinger's widely used computational platform enables highly accur. businesswire.com - 1 month ago
Schrodinger (SDGR) Moves 27.4% Higher: Will This Strength Last? Schrodinger (SDGR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term. zacks.com - 1 month ago
Schrödinger Poised For Growth As FDA Shifts Away From Animal Testing (Upgrade) Schrödinger's stock surged after the FDA's initiative to phase out animal testing, benefiting its computational drug discovery platform. The company has strong collaborations with big pharma and a promising internal pipeline, despite past financial struggles and intense competition. Schrödinger's predictive toxicology initiative aligns with regulatory trends, enhancing drug development efficiency and safety. seekingalpha.com - 1 month ago
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today reported that on March 15, 2025, the company granted (i) a non-statutory stock option to purchase 1,575 shares of the company's common stock to one newly hired employee and (ii) restricted stock units (RSUs) with respect to 6,943 shares of the company's common stock to seven newly hired employees. These grants were made pursuant to the company's 2021 Inducement Equity Incentive Plan, were approved by the compensation committee of. businesswire.com - 2 months ago
Schrödinger Expands Board of Directors with Appointment of Bridget van Kralingen NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. today announced the appointment of Bridget van Kralingen to its Board of Directors, effective March 7, 2025. businesswire.com - 2 months ago
Schrödinger: Still Waiting On A Catalyst Schrödinger's Q4 2024 results and 2025 guidance were solid, yet the company's share price remains low due to ongoing losses. Cash burn is likely to moderate going forward, as investments in the company's internal pipeline have now stabilized. Regardless, cash burn concerns are misplaced, as Schrödinger has demonstrated that it can manage its liquidity position through things like partnerships and licensing. seekingalpha.com - 2 months ago
8. Profile Summary

Schrödinger, Inc. SDGR

image
COUNTRY US
INDUSTRY Medical - Healthcare Information Services
MARKET CAP $ 1.74 B
Dividend Yield 0.00%
Description Schrödinger, Inc., together with its subsidiaries, provides physics-based software platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on selling its software for drug discovery in the life sciences industry, as well as to customers in materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.
Contact 1540 Broadway, New York, NY, 10036 https://www.schrodinger.com
IPO Date Feb. 6, 2020
Employees 891
Officers Prof. William Goddard III Co-Founder & Scientific Advisor Ms. Jaren Irene Madden Senior Vice President of Investor Relations & Corporate Affairs Dr. Karen Akinsanya Ph.D. President of Research & Development Therapeutics Dr. Ramy Farid Ph.D. Chief Executive Officer, President & Director Mr. Kenneth Patrick Lorton Executive Vice President, Chief Technology Officer & Chief Operating Officer of Software Dr. Robert Lorne Abel Ph.D. Executive Vice President, Chief Scientific Officer of Platform and Head of Modeling R&D Ms. Yvonne Tran Esq. Corporate Secretary, Chief Legal & People Officer Dr. Richard A. Friesner Ph.D. Co-Founder, Scientific Advisory Chairman and Director Dr. Geoffrey Craig Porges MBBS Executive Vice President & Chief Financial Officer Mr. Shane Brauner Executive Vice President & Chief Information Officer